secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001193125-23-084520
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos Therapeutics appoints Dr. Robert Hofmeister to board, replacing Dr. Christopher Bowden
--------------------------------------------------------------------------------

- Christopher Bowden resigned from board effective March 30, 2023; no disagreement with company.
- Robert Hofmeister appointed as director effective March 30, 2023, filling Bowden's vacancy.
- Hofmeister brings over 25 years of T-cell therapy experience; previously CSO at TCR2 Therapeutics.
- Hofmeister receives initial option for 150,000 shares and pro-rated annual grant for 16,667 shares.
- Hofmeister appointed to Corporate Governance and Nominating and Compensation Committees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523084520/0001193125-23-084520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523084520/d490816d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-084520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer